Sentiment & Themes Emerging From JPM 2024
LifeSciVC
JANUARY 16, 2024
The expectation that Pharma will continue buy-ups here is helping to fuel conviction for another strong year ahead for M&A, especially for those acquirers who will rely on inorganic acquisition to build in areas under-represented by internal R&D (e.g., Small molecule GLP1s?
Let's personalize your content